Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

PROG - Biora Therapeutics Inc


Close
0.8845
-0.032   -3.595%

Share volume: 2,777,710
Last Updated: Fri 06 May 2022 10:00:01 PM CEST
Medical Laboratories : -2.05%

PREVIOUS CLOSE
CHG
CHG%

$0.92
-0.03
-3.47%
This ticker is disabled and data are no longer maintained and up to date.
Fundamental analysis
32%
Profitability 26%
Dept financing 38%
Liquidity 17%
Performance 40%
Company vs Stock growth
vs
Performance
5 Days
5.65%
1 Month
-25.67%
3 Months
-43.66%
6 Months
-74.87%
1 Year
-67.48%
2 Year
-93.26%
Key data
Stock price
$0.88
P/E Ratio 
0.00
DAY RANGE
N/A - N/A
EPS 
$0.00
52 WEEK RANGE
$0.66 - $6.20
52 WEEK CHANGE
-$0.67
MARKET CAP 
162.924 M
YIELD 
N/A
SHARES OUTSTANDING 
184.199 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05/12/2022
BETA 
1.57
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$3,682,441
AVERAGE 30 VOLUME 
$4,033,532
Company detail
CEO: Harry Stylli
Region: US
Website: www.progenity.com
Employees: 642
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Medical Laboratories
Sector: Health Care and Social Assistance

Progenity, Inc. is a biotechnology company with an established track record of success in developing and commercializing molecular testing products, as well as innovating in the field of precision medicine. Progenity provides in vitro molecular tests designed to improve lives by providing actionable information that helps guide patients and physicians in making medical decisions during key life stages. The company applies a multi-omics approach, combining genomics, epigenomics, proteomics, and metabolomics to its molecular testing products and to the development of a suite of investigational ingestible devices designed to provide precise diagnostic sampling and drug delivery solutions. Progenity’s vision is to transform healthcare to become more precise and personal by improving diagnoses of disease and improving patient outcomes through localized treatment with targeted therapies.

Recent news